NASDAQ:GRTS Gritstone bio (GRTS) Stock Forecast, Price & News $1.93 +0.12 (+6.63%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$1.79▼$1.9550-Day Range$1.66▼$3.0352-Week Range$1.64▼$5.85Volume819,519 shsAverage Volume698,059 shsMarket Capitalization$171.60 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Gritstone bio MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside197.9% Upside$5.75 Price TargetShort InterestBearish5.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 3 Articles This WeekInsider TradingAcquiring Shares$22,800 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.20) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.71 out of 5 starsMedical Sector864th out of 1,006 stocksBiological Products, Except Diagnostic Industry139th out of 167 stocks 3.3 Analyst's Opinion Consensus RatingGritstone bio has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.75, Gritstone bio has a forecasted upside of 197.9% from its current price of $1.93.Amount of Analyst CoverageGritstone bio has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.16% of the float of Gritstone bio has been sold short.Short Interest Ratio / Days to CoverGritstone bio has a short interest ratio ("days to cover") of 6.8.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldGritstone bio does not currently pay a dividend.Dividend GrowthGritstone bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRTS. Previous Next 2.0 News and Social Media Coverage News SentimentGritstone bio has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Gritstone bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for GRTS on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gritstone bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.61% of the stock of Gritstone bio is held by insiders.Percentage Held by Institutions48.06% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gritstone bio are expected to decrease in the coming year, from ($1.20) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gritstone bio is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gritstone bio is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGritstone bio has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Gritstone bio (NASDAQ:GRTS) StockGritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.Read More Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTS Stock News HeadlinesMay 28, 2023 | fool.comGritstone Bio (NASDAQ: GRTS)May 27, 2023 | americanbankingnews.comGritstone bio, Inc. (NASDAQ:GRTS) Insider Buys $22,800.00 in StockJune 1, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 26, 2023 | benzinga.comGritstone Bio Stock (NASDAQ:GRTS), Insider Trading ActivityMay 17, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Gritstone bio, Inc. Decreased by HC Wainwright (NASDAQ:GRTS)May 16, 2023 | msn.comHC Wainwright & Co. Reiterates Gritstone Bio (GRTS) Buy RecommendationMay 16, 2023 | finance.yahoo.comThe Consensus EPS Estimates For Gritstone bio, Inc. (NASDAQ:GRTS) Just Fell DramaticallyMay 11, 2023 | msn.comGritstone Bio: Q1 Earnings InsightsJune 1, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 11, 2023 | msn.comGritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2023 | finance.yahoo.comGritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesMay 3, 2023 | finance.yahoo.comGritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023April 27, 2023 | msn.comGritstone bio Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseApril 21, 2023 | finance.yahoo.comBoth individual investors who control a good portion of Gritstone bio, Inc. (NASDAQ:GRTS) along with institutions must be dismayed after last week's 14% decreaseApril 17, 2023 | finance.yahoo.comGritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual MeetingApril 17, 2023 | finance.yahoo.comGritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)April 14, 2023 | americanbankingnews.comGritstone bio (NASDAQ:GRTS) versus Ablynx (OTCMKTS:ABLYF) Head-To-Head SurveyApril 5, 2023 | americanbankingnews.comGritstone bio (NASDAQ:GRTS) and IN8bio (NASDAQ:INAB) Head to Head SurveyApril 4, 2023 | finance.yahoo.comGritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023April 3, 2023 | americanbankingnews.comGritstone bio (NASDAQ:GRTS) Coverage Initiated by Analysts at Evercore ISIApril 2, 2023 | benzinga.comIs Gritstone bio Inc (GRTS) a Good Choice in Biotechnology Friday?April 1, 2023 | americanbankingnews.comB. Riley Comments on Gritstone bio, Inc.'s Q1 2023 Earnings (NASDAQ:GRTS)March 28, 2023 | msn.comGritstone bio draws Buy rating at B. Riley on mRNA potentialMarch 28, 2023 | americanbankingnews.comGritstone bio (NASDAQ:GRTS) Now Covered by Analysts at B. RileyMarch 17, 2023 | benzinga.comGritstone Bio Stock (NASDAQ:GRTS), Short Interest ReportMarch 15, 2023 | finance.yahoo.comGritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual MeetingMarch 13, 2023 | finance.yahoo.comGritstone bio, Inc. (NASDAQ:GRTS) Q4 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTS Company Calendar Last Earnings3/09/2023Today5/31/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRTS CUSIPN/A CIK1656634 Webwww.gritstoneoncology.com Phone(510) 871-6100FaxN/AEmployees193Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.75 High Stock Price Forecast$8.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+197.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,690,000.00 Net Margins-820.91% Pretax Margin-820.91% Return on Equity-81.55% Return on Assets-57.36% Debt Debt-to-Equity Ratio0.21 Current Ratio6.27 Quick Ratio6.27 Sales & Book Value Annual Sales$19.94 million Price / Sales8.61 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book1.22Miscellaneous Outstanding Shares88,910,000Free Float84,815,000Market Cap$171.60 million OptionableNot Optionable Beta0.53 Key ExecutivesAndrew R. AllenPresident, Chief Executive Officer & DirectorErin E. JonesChief Operating Officer & Executive Vice PresidentVassiliki Celia EconomidesChief Financial Officer & Executive Vice PresidentKarin JoossExecutive VP & Head-Research & DevelopmentVijay YabannavarChief Technical Development Officer & Executive VPKey CompetitorsGraphite BioNASDAQ:GRPHAtara BiotherapeuticsNASDAQ:ATRAC4 TherapeuticsNASDAQ:CCCCVaxartNASDAQ:VXRTAdaptimmune TherapeuticsNASDAQ:ADAPView All CompetitorsInsiders & InstitutionsVassiliki EconomidesBought 12,000 shares on 5/23/2023Total: $22,800.00 ($1.90/share)Balyasny Asset Management L.P.Bought 318,490 shares on 5/16/2023Ownership: 2.669%Geode Capital Management LLCBought 32,612 shares on 5/16/2023Ownership: 0.837%State Street CorpSold 7,000 shares on 5/16/2023Ownership: 0.307%Squarepoint Ops LLCBought 59,308 shares on 5/16/2023Ownership: 0.067%View All Insider TransactionsView All Institutional Transactions GRTS Stock - Frequently Asked Questions Should I buy or sell Gritstone bio stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GRTS shares. View GRTS analyst ratings or view top-rated stocks. What is Gritstone bio's stock price forecast for 2023? 5 brokerages have issued 12 month price targets for Gritstone bio's shares. Their GRTS share price forecasts range from $2.00 to $8.00. On average, they predict the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 197.9% from the stock's current price. View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts. How have GRTS shares performed in 2023? Gritstone bio's stock was trading at $3.45 on January 1st, 2023. Since then, GRTS shares have decreased by 44.1% and is now trading at $1.93. View the best growth stocks for 2023 here. When is Gritstone bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our GRTS earnings forecast. How were Gritstone bio's earnings last quarter? Gritstone bio, Inc. (NASDAQ:GRTS) announced its quarterly earnings data on Thursday, March, 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.01. The firm earned $4.26 million during the quarter, compared to the consensus estimate of $3.08 million. Gritstone bio had a negative net margin of 820.91% and a negative trailing twelve-month return on equity of 81.55%. What ETFs hold Gritstone bio's stock? ETFs with the largest weight of Gritstone bio (NASDAQ:GRTS) stock in their portfolio include Direxion mRNA ETF (MSGR) and ETFMG Treatments Testing and Advancements ETF (GERM).ALPS Medical Breakthroughs ETF (SBIO). What is Andrew Allen's approval rating as Gritstone bio's CEO? 1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Gritstone bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL). When did Gritstone bio IPO? (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager. What is Gritstone bio's stock symbol? Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS." Who are Gritstone bio's major shareholders? Gritstone bio's stock is owned by many different institutional and retail investors. Top institutional investors include Balyasny Asset Management L.P. (2.67%), BlackRock Inc. (2.17%), Assenagon Asset Management S.A. (1.75%), Bank of America Corp DE (1.19%), FMR LLC (0.90%) and Geode Capital Management LLC (0.84%). Insiders that own company stock include Erin Jones, Raphael Rousseau and Vassiliki Economides. View institutional ownership trends. How do I buy shares of Gritstone bio? Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gritstone bio's stock price today? One share of GRTS stock can currently be purchased for approximately $1.93. How much money does Gritstone bio make? Gritstone bio (NASDAQ:GRTS) has a market capitalization of $171.60 million and generates $19.94 million in revenue each year. The company earns $-119,690,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. How many employees does Gritstone bio have? The company employs 193 workers across the globe. How can I contact Gritstone bio? Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The official website for the company is www.gritstoneoncology.com. The company can be reached via phone at (510) 871-6100 or via email at ir@gritstone.com. This page (NASDAQ:GRTS) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gritstone bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.